Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 360° synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of stomach cancer
3.2.1.2 Advancements in diagnostic techniques
3.2.1.3 Development of targeted therapies
3.2.1.4 Rising awareness and screening programs
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of treatment
3.2.2.2 Side effects and safety concerns associated with cancer therapies
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.5.1 Core technologies
3.5.2 Adjacent technologies
3.6 Pricing analysis, 2023
3.6.1 By region
3.6.2 By key player
3.7 Future market trends
3.8 Porter’s analysis
3.9 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Chemotherapy
5.3 Immunotherapy
5.4 Targeted therapy
Chapter 6 Market Estimates and Forecast, By Indication, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Gastric cancer /gastroesophageal junction cancer
6.3 Gastrointestinal stromal tumors
Chapter 7 Market Estimates and Forecast, By Drug Class, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 PD-1/PD-L1 inhibitors
7.3 HER2 antagonists
7.4 VEGFR2 antagonists
7.5 Other drug classes
Chapter 8 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Oral
8.3 Injectable
Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 Hospital pharmacies
9.3 Specialty & retail pharmacies
9.4 Other distribution channels
Chapter 10 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
10.1 Key trends
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Spain
10.3.5 Italy
10.3.6 Netherlands
10.3.7 Rest of Europe
10.4 Asia Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.4.6 Rest of Asia Pacific
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Argentina
10.5.4 Rest of Latin America
10.6 Middle East and Africa
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 UAE
10.6.4 Rest of Middle East and Africa
Chapter 11 Company Profiles
11.1 AstraZeneca PLC
11.2 Bristol Myers Squibb Company
11.3 Bayer AG
11.4 Biocon Limited
11.5 Celltrion Inc.
11.6 Eli Lilly and Company
11.7 F. Hoffmann-La Roche Ltd.
11.8 Ipsen Pharma
11.9 Merck & Co., Inc.
11.10 Novartis AG
11.11 Otsuka Holdings Co., Ltd.
11.12 Pfizer Inc.
11.13 Samsung Biologics Co., Ltd.
11.14 Teva Pharmaceutical Industries Ltd.
11.15 Viatris Inc.
